Bayer grows Asian diabetes care business:
This article was originally published in Clinica
Executive Summary
Bayer HealthCare is adding two new blood glucose management systems, Breeze and Brio, to its offerings in China and Korea in a bid to capitalise on the growing, and yet underpenetrated, diabetes care market in Asia. The company (part of the German drugs giant Bayer) will also be conducting information campaigns in both countries to educate people about the value of better diabetes management through regular blood glucose monitoring, diet, exercise and medication. The number of new diabetes cases in Asia is expected to more than double by 2025, according to the International Diabetes Federation. Of the 40 million in China suffering from the disorder, only 2% own a blood glucose meter for regular monitoring of their blood glucose level.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.